ScandiDos ABOSTO:SDOS +6.25%47 5-Year ROIIC % is 13.71 as of Apr. 2026. GuruFocus rates OSTO:SDOS with a GF Score™ of 47/100 and a GF Value™ of kr1.14 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 733 Medical Devices & Instruments companies, ScandiDos AB ranks better than 68.21% on this metric.
5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year.
ScandiDos AB's 5-Year ROIIC % for the quarter that ended in Apr. 2026 was 13.71%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for ScandiDos AB's 5-Year ROIIC % or its related term are showing as below:
OSTO:SDOS's 5-Year ROIIC % is ranked better than 68.21% of 733
companies
in the Medical Devices & Instruments industry
Industry Median: 1.04
vs OSTO:SDOS: 13.71
ScandiDos AB (OSTO:SDOS) 5-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
ScandiDos AB 5-Year ROIIC % Related Terms
ScandiDos AB 5-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for ScandiDos AB's 5-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:SDOS vs ABT, SYK, MDT: 5-Year ROIIC % Comparison
For the Medical Devices subindustry, ScandiDos AB's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ScandiDos AB 5-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ScandiDos AB's 5-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where ScandiDos AB's 5-Year ROIIC % falls into.
ScandiDos AB's 5-Year ROIIC % for the quarter that ended in Apr. 2026 is calculated as:
5-Year ROIIC %
=
5-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
5-Year Incremental Invested Capital**
=
( -2.986 (Apr. 2026) - -2.0601928 (Apr. 2021) )
/
( 58.395 (Apr. 2026) - 65.146 (Apr. 2021) )
=
-0.9258072
/
-6.751
=
13.71%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
ScandiDos AB (OSTO:SDOS) has a 5-Year ROIIC % of 13.71 as of Apr. 2026. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on ScandiDos AB and its competitors. According to the industry distribution chart, ScandiDos AB ranks #233 out of 733 companies in the Medical Devices & Instruments industry, placing it in the top 31.8%.
Is ScandiDos AB's 5-Year ROIIC % too high?
ScandiDos AB's current 5-Year ROIIC % is 13.71. The Medical Devices & Instruments industry median 5-Year ROIIC % is 1.04. ScandiDos AB's value of 13.71 is 1218.3% above this industry median. Based on the distribution chart, ScandiDos AB ranks #233 out of 733 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, ScandiDos AB has a GF Score™ of 47/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ScandiDos AB's 5-Year ROIIC % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, ScandiDos AB ranks #233 out of 733 companies for 5-Year ROIIC %. This puts ScandiDos AB in the upper half of its industry. The industry median 5-Year ROIIC % is 1.04. ScandiDos AB's value of 13.71 is 1218.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year ROIIC % for a Medical Devices & Instruments company?
The median 5-Year ROIIC % among Medical Devices & Instruments companies is 1.04, based on 733 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ScandiDos AB's current 5-Year ROIIC % of 13.71 is 1218.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year ROIIC % mean?
A high 5-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on ScandiDos AB and its competitors. For the Medical Devices & Instruments industry, the median 5-Year ROIIC % is 1.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ScandiDos AB's current 5-Year ROIIC % is 13.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ScandiDos AB stock overvalued right now?
Based on GuruFocus' analysis, ScandiDos AB (OSTO:SDOS) is currently considered Modestly Undervalued. The stock's GF Value™ is kr1.14, compared to a current price of kr0.85 — trading 25.4% below its estimated fair value. The current 5-Year ROIIC % is 13.71 and 1218.3% above the Medical Devices & Instruments industry median of 1.04. ScandiDos AB's overall GF Score™ is 47/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year ROIIC % calculated?
5-Year ROIIC % is calculated from a company's financial statements. For ScandiDos AB (OSTO:SDOS), the current 5-Year ROIIC % is 13.71 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ScandiDos AB (OSTO:SDOS) Overvalued in 2026?
Based on GuruFocus' analysis, ScandiDos AB stock appears to be undervalued.
The current stock price of kr0.85 is trading 25.4% below its estimated GF Value™ of kr1.14.
GuruFocus considers ScandiDos AB to be Modestly Undervalued.
Key valuation signals for OSTO:SDOS:
5-Year ROIIC %: 13.71
GF Value™: kr1.14 vs. price of kr0.85 (25.4% below fair value)
Industry Position: 1218.3% above the Medical Devices & Instruments median (#233 of 733)
No single metric tells the full story. See the OSTO:SDOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ScandiDos AB is engaged in providing radiation therapy for cancer. Its product, Delta4 Phantom+, and its various hardware and software options are at the heart of everything ScandiDos does, from product development and production to marketing, sales, and customer support. With Delta4 HexaMotion ScandiDos has successfully developed a motion platform that recreates the movement of the tumor in six dimensions and independently simulates the patient's breathing movement.
47GF Score
Get the complete analysis for OSTO:SDOS
5-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:SDOS has been successfully added to your 
